New Delhi: Sri Sri Ravishankar’s Tattva has launched a classical Siddha medicine, Kabasura Kudineer, which it claims helps in the prevention and treatment of coronavirus. Under the guidance of Germany-based Frankfurt Innovation Center for Biotechnology, the company tested the drug combination for anti-inflammatory and immune-boosting Ayurvedic agents and their effectiveness against the novel coronavirus. A research study by Frankfurt Innovation Center for Biotechnology (FIZ) shows the efficacy of Kabasura Kudineer tablet, along with other Ayurveda medicines, for screening inhibitors of the SARS-CoV-2 Spike: ACE2 interaction. The study found that Kabasuraa Kudineer tablets were the strongest inhibitor (84%) of Spike glycoprotein in coronavirus strains, in restricting entry of the virus into cells in invitro studies.
During a virtual press conference, the company emphasised the use of their medicine for the…
World Homeopathy Day – Complementary Medicine for Current Era
World Homeopathy Day – Complementary Medicine for Current Era - The CSR Journal World Homeopathy Day is observed on April 10 to mark the...